What the FDA labels say about taking them together
Desmopressin and lamotrigine
Desmopressin's FDA label of February 3, 2021 names lamotrigine in its drug interactions section; the lamotrigine labels PlainMeds reads (3) do not name desmopressin. The desmopressin label: “The concomitant administration of drugs that may increase the risk of water intoxication with hyponatremia, should be performed with caution.”
Check it at the source: the desmopressin FDA label on DailyMed (effective February 3, 2021, Ferring Pharmaceuticals Inc.); the lamotrigine FDA label on DailyMed (effective October 10, 2025).
What does the desmopressin label say about lamotrigine?
Desmopressin label, drug interactionsThe concomitant administration of drugs that may increase the risk of water intoxication with hyponatremia, (e.g. tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, NSAIDs, lamotrigine and carbamazepine) should be performed with caution.
Stimate label (Ferring Pharmaceuticals Inc., July 22, 2026), drug interactionsDrugs that may Increase Risk of Hyponatremia The concomitant administration of STIMATE with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, NSAIDs, lamotrigine, and carbamazepine) requires more frequent serum sodium monitoring [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6 )].
Desmoda label (Eton Pharmaceuticals, Inc., March 2, 2026), drug interactionsDRUG INTERACTIONS 7.1 Other Drugs that may Increase Risk of Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine).
Desmopressin Acetate label (Nordic Pharma, Inc., October 24, 2025), warnings and precautionsPatients with conditions associated with fluid and electrolyte imbalance (i.e., cystic fibrosis, heart failure, and renal disorders), geriatric and pediatric patients, patients receiving concomitant treatments that also cause hyponatremia (i.e., tricyclic antidepressants, selective serotonin reuptake inhibitors, nonsteroidal anti-inflammatory drugs, chlorpromazine, opiate analgesics, carbamazepine, lamotrigine, thiazide diuretics and chlorpropamide), and patients with habitual or psychogenic polydipsia who may drink excessive amounts of water, may be at increased risk of hyponatremia [see Contraindications (4) ].
Source: FDA drug label (Stimate, NDA020355), Ferring Pharmaceuticals Inc., effective July 22, 2026 (SPL set f5ada39c-20ed-4500-9dce-1e4ab642a358), via openFDA
Source: FDA drug label (Desmoda, NDA219873), Eton Pharmaceuticals, Inc., effective March 2, 2026 (SPL set 4c0e1356-d14f-cfb4-e063-6294a90acd27), via openFDA
Source: FDA drug label (Desmopressin Acetate, NDA018938), Nordic Pharma, Inc., effective October 24, 2025 (SPL set 29df0492-f7ef-47bb-aa67-4ef9e5c2846f), via openFDA
Source: FDA drug label (DDAVP), Ferring Pharmaceuticals Inc., effective February 3, 2021 (SPL set 6d55baa9-2b62-469c-93ae-3909ab249332), via openFDA; the full label on DailyMed
What does the lamotrigine label say about desmopressin?
Lamotrigine's label (effective October 10, 2025) and its 2 other brand-application labels do not name desmopressin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (LAMICTAL), GlaxoSmithKline LLC, effective October 10, 2025 (SPL set d7e3572d-56fe-4727-2bb4-013ccca22678), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Desmopressin | Lamotrigine | |
|---|---|---|
| Labeled for | n/a | Seizures and epilepsy, Bipolar disorder |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $19.15 per mL 40 mcg/10 mL vial | $0.0268 per tablet 25 mg tablet |
| Shortage now | Listed; available | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once